1 Min Read
July 13 (Reuters) - Innovation Pharmaceuticals:
* Innovation Pharmaceuticals phase 2 PoC trial for inflammatory bowel disease achieves induction of remission in a majority of patients treated with Brilacidin Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.